Rabeprazole Versus Omeprazole in Preventing Relapse of Erosive or Ulcerative Gastroesophageal Reflux Disease
- 1 January 2000
- journal article
- clinical trial
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 45 (5) , 845-853
- https://doi.org/10.1023/a:1005548318996
Abstract
Gastroesophageal reflux disease (GERD) is a chronic condition, with 50–80% of patients experiencing recurrence within one year of completing initial treatment. In patients with erosive GERD,...Keywords
This publication has 24 references indexed in Scilit:
- Double‐blind, placebo‐controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 1999
- Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 1999
- Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer—a European multicentre studyAlimentary Pharmacology & Therapeutics, 1998
- Different management for Helicobacter pylori positive and negative patients with gastro-oesophageal reflux disease?Gut, 1998
- RabeprazoleDrugs, 1998
- Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 1997
- Critical issues in the management of gastroesophageal reflux disease.1995
- Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.Gut, 1994
- Medical treatment of reflux esophagitis.1992
- The potency of substituted benzimidazoles such as E3810, omeprazole, RO 18-5364 to inhibit gastric H+,K+-ATPase is correlated with the rate of acid-activation of the inhibitorBiochemical Pharmacology, 1990